Navigation Links
CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
Date:11/6/2009

ad and neck cancer. CEL-SCI is also developing an immunotherapy to prevent and treat swine and other influenzas using its L.E.A.P.S. technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, lack of regulatory clearance to proceed with clinical trials, an inability to duplicate the clinical results demonstrated in clinical studies that have been completed or that are initiated in the future, timely development of any potential products that can be shown to be safe and effective, unwillingness of regulatory authorities to engage in further regulatory dialogue, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has Potential to Slow Damage Caused by Rheumatoid Arthritis
2. CEL-SCI Corporation to Raise $20 Million in Registered Direct Offering
3. CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes
4. CEL-SCI Completes $5.85 Million Registered Direct Offering
5. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
6. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
7. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
8. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
9. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
10. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
11. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Asheville, North Carolina (PRWEB) September 30, 2014 ... cloud readiness and IT Infrastructure analytics across data ... announced it has achieved an important milestone of ... problems and plan for important projects such as ... workload migrations. , The strong customer engagement ...
(Date:9/30/2014)... Washington DC. (PRWEB) September 30, 2014 ... has developed Lyricz iPhone App for another great social ... release of LYRICZ App for iPhone®, iPad®, and iPod ... 30 second snippets of music from their pre-populated ITunes ... associate the chosen song’s album art or photo of ...
(Date:9/30/2014)... Albany, New York (PRWEB) September 30, 2014 ... Research, a U.S.-based market intelligence agency states that the ... a value of USD 18.5 billion by the end ... was valued at USD 10.3 billion in 2012, will ... develop into a USD 18.5 billion worth market by ...
(Date:9/30/2014)... 2014 MyServer2Go.com made an ... Best VPS Hosting this year for its quality VPS ... price. , MyServer2Go.com is a professional and targeted ... services. And this announcement will help webmasters find the ... MyServer2Go.com, Arvixe ( http://www.arvixe.com ) is one of the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Speaking on ... OMICS Group observed ‘Nursing Conference’ as a remarkable event, ... and medium medical and clinical research and diagnostic companies, ... conference as a perfect platform to share experience, foster ... around the world. Nursing Conference is a forum to ...
Breaking Medicine News(10 mins):Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:LYRICZ App for iPhone®, Helps You Share Images with Music to Inspire and Influence 2Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 2Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 3Health News:Arvixe Is Named Best VPS Hosting by MyServer2Go.com 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3
... way deter the elders from chatting or surfing the Internet ... net on par// with the youngsters. ,The survey conducted ... Marketing Services has revealed that senior netizens are a fast-growing ... million by 2008. ,These seniors - who number ...
... very common in North America with an estimated 400,000 people ... these //people have their hearts pumping again and only 6 ... causes of death after the heart is restarted is brain ... Society for Academic Emergency Medicine Annual Meeting, May 18-21, in ...
... get themselves screened for HIV, city-run medical clinics have relaxed ... the new rule, counseling sessions and written informed consent is ... is a verbal consent from the patient. ,This ... relaxed with respect to consent and counseling. Two hospitals and ...
... have issued a warning to drug users about the quality ... is being sold on the west coast// of Scotland has ... the beginning of this year there has been 82 inquiries ... same period last year. The police have said that not ...
... say may fight two dangerous germs that bedevil hospitals//. ... Laboratories and his colleagues looked at 250,000 extracts from ... from around the world, the health portal HealthDay News ... African soil, which they say could fight staph an ...
... Following high incidence of a potentially dangerous infection associated ... Bausch & Lomb//, those in Hong Kong, US and ... controversial product has been withdrawn from sales. ... product. However the company has been unable to claim ...
Cached Medicine News:Health News:Elders Too Are Keen To Chat On Internet On Par With Youngsters 2Health News:Survival After Cardiac Arrest Is Aided By Cooling 2
(Date:9/30/2014)... Sept. 30, 2014  HealthLoop® released an app version ... in iOS 8 and allows people to share medical ... harnesses native iOS technologies to enhance the HealthLoop experience ... connection with their doctors between visits. ... data they collect is exciting," says HealthLoop founder Dr. ...
(Date:9/30/2014)... Sept. 30, 2014 BioStructures, LLC has ... Association of Tissue Banks (AATB), it was announced ... Officer. Accreditation follows an intensive nine-month ... trained AATB inspector.  It establishes that the level ... facility meets or exceeds the standards set by ...
(Date:9/30/2014)... VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... tissue diagnostics market, Frost & Sullivan recognizes Ventana ... Roche Group, with the 2014 North American Frost ... to strict quality practices along with a focus ... Ventana a global leader in tissue-based cancer diagnostic ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Biostructures, LLC Earns AATB Accreditation 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... SAN RAMON, Calif., Nov. 29, 2011 Odyssey ... biologically-relevant pathways in human cells, announced today that ... a laser-based confocal imaging platform from GE Healthcare, ... Odyssey Thera applies a systems ...
... Nov. 29, 2011 A new study in The ... a novel mechanism that cancer cells may use to escape ... cells induce tumor cell resistance to cytotoxic T cells in ... Center in Tampa, Fla., shows that a specific type of ...
Cached Medicine Technology:Odyssey Thera is First to Install Next Generation High-Content Imaging Capability 2New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 2New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: